Gilead hepatitis C drug shows promise in late-stage trial

(Reuters) - Gilead Sciences said a late-stage trial of its experimental hepatitis C treatment showed that the virus was not detected in 78 percent of patients taking the drug, 12 weeks after completing therapy. The trial, named Positron, was testi...

Source: http://health.yahoo.net/news/s/nm/gilead-hepatitis-c-drug-shows-promise-in-late-stage-trial

homepage here site here website here citation